{"result": "(\"entity\"<|>GALACTOSEMIA<|>EVENT<|>Galactosemia is a metabolic disorder characterized by the inability to properly metabolize galactose, leading to various complications if not treated with a proper diet.)\n##\n(\"entity\"<|>AFROAMERICANS<|>PERSON<|>Afroamericans are a demographic group that is frequently affected by the clinical variant of galactosemia, particularly with the p.Ser135Leu mutation.)\n##\n(\"entity\"<|>AFRICANS<|>PERSON<|>Africans, particularly those native to South Africa, are also commonly affected by the clinical variant of galactosemia, sharing similar genetic mutations.)\n##\n(\"entity\"<|>DUARTE VARIANT<|>EVENT<|>The Duarte variant of galactosemia is a biochemical variant characterized by partial residual GALT activity, leading to milder symptoms compared to classic galactosemia.)\n##\n(\"entity\"<|>GALT<|>ORGANIZATION<|>GALT (Galactose-1-phosphate uridylyltransferase) is the enzyme whose activity is deficient in individuals with galactosemia, leading to the accumulation of galactose and its metabolites.)\n##\n(\"entity\"<|>NEONATAL SCREENING<|>EVENT<|>Neonatal screening for galactosemia is a program that detects elevated levels of galactose and GALT activity in newborns to diagnose the disorder early.)\n##\n(\"entity\"<|>HOSPITAL<|>ORGANIZATION<|>Hospitals are medical institutions where newborns are screened for galactosemia and treated if diagnosed.)\n##\n(\"relationship\"<|>GALACTOSEMIA<|>AFROAMERICANS<|>Galactosemia is a condition that frequently affects Afroamericans, particularly those with specific genetic mutations.<|>7)\n##\n(\"relationship\"<|>GALACTOSEMIA<|>AFRICANS<|>Galactosemia is a condition that frequently affects Africans, especially those native to South Africa, due to specific genetic mutations.<|>7)\n##\n(\"relationship\"<|>DUARTE VARIANT<|>GALACTOSEMIA<|>The Duarte variant is a specific type of galactosemia that presents with milder symptoms due to partial GALT activity.<|>8)\n##\n(\"relationship\"<|>NEONATAL SCREENING<|>GALACTOSEMIA<|>Neonatal screening is a crucial process for the early detection of galactosemia in newborns, allowing for timely intervention.<|>9)\n##\n(\"relationship\"<|>HOSPITAL<|>NEONATAL SCREENING<|>Hospitals conduct neonatal screening programs to identify cases of galactosemia in newborns.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: embargo, a pesar de la instauración precoz de las modificaciones dietéticas de forma correcta los pacientes suelen sufrir algún tipo de secuelas, como dificultades en el lenguaje, menor desarrollo intelectual del esperado, síntomas extrapiramidales (ataxia, alteraciones de la coordinación, temblor fino), trastornos de aprendizaje, cataratas, retraso del crecimiento y fallo ovárico precoz. No obstante, estas complicaciones y su gravedad tienen gran variabilidad entre diferentes individuos.\n\n- Variante clínica de galactosemia, causada por un déficit grave de la actividad enzimática (actividad residual 1-10% en eritrocitos y/o hígado). La forma más frecuente es típica de los afroamericanos y los africanos nativos de Sudáfrica, con la mutación característica p.Ser135Leu en forma homocigota. Las manifestaciones clínicas son similares a la galactosemia clásica, y al igual que en ella desaparecen con el tratamiento dietético precoz. Sin embargo, no suelen tener complicaciones a largo plazo. Otros heterocigotos compuestos, como aquellos p.Ser135Leu/p.Gln188Arg tienen también menos complicaciones que los pacientes con galactosemia clásica. Los niveles de galactosa se encuentran elevados en similar medida que en la forma clásica. La Gal-1-P eritrocitaria está elevada pero habitualmente en niveles no tan altos como en la forma clásica (> 10 mg/dl), y cuando se sigue la dieta libre de galactosa de forma correcta se normaliza.\n\n- Variante bioquímica de Galactosemia, con actividad GALT parcial residual >15% en eritrocitos. Los niveles de Gal-1-P en eritrocitos son mayores de1 mg/dl sin tratamiento dietético, y normales si se cumple la dieta sin galactosa. La más frecuente es la variante Duarte, en la que los individuos son heterocigotos compuestos con una mutación clásica y una mutación Duarte (D2) (mutación c.[940A>G; c.-119_116delGTCA]) (G/ D) que mantiene una actividad GALT en los eritrocitos entre el 15 y el 25%. Habitualmente se encuentran asintomáticos y sin complicaciones a largo plazo aunque no realicen ningún tipo de modificación dietética; solo exhiben alteraciones bioquímicas de los niveles de galactosa y sus metabolitos, mucho más leves que en la forma clásica y las variantes clínicas. Por este motivo algunos autores no la consideran una enfermedad como tal. Sin embargo, hay descritos casos de individuos con complicaciones agudas que se resuelven tras restricción dietética, y también estudios de pequeños grupos de pacientes con alteraciones crónicas del desarrollo neurológico, sobre todo del lenguaje. Por todo ello se necesitan estudios a largo plazo que determinen si estos sujetos tienen riesgo o no de complicaciones en caso de que no sigan una dieta sin lactosa.\n\nLos homocigotos para alelos duarte (D/D) tienen una actividad GALT eritrocitaria del 50%, pero no existen suficientes datos publicados como para asegurar que están libres de manifestaciones. Los portadores de un alelo Duarte y uno sano tienen una actividad > 75% y son considerados portadores sanos.\n\nLa galactosemia puede diagnosticarse de forma precoz tras el nacimiento, y en algunos lugares está incluida en los programas de screening neonatal. Estos programas detectan los niveles elevados de galactosa total (Galactosa + Gal-1-P eritrocitaria) y la actividad enzimática GALT en sangre de talón. Habitualmente se realiza primero la determinación de galactosa total; se considera un test positivo si el nivel de galactosa es > 14,5 mg/dl. En estos casos se recomienda repetirlo, y si fuera positivo por segunda vez se deberá confirmar el diagnóstico mediante la determinación de la actividad enzimática. Si en el test inicial el nivel es > 5 mg/dl se cuantificará directamente la actividad enzimática. Hay que tener en cuenta que el test de screening para galactosemia puede ser positivo en cualquiera de los déficits enzimáticos del metabolismo de la galactosa, sin diferenciar entre ellos, por lo que siempre requerirá determinar la actividad enzimática y confirmación mediante estudio genético.\n\nDe igual forma, en los pacientes en los que se sospeche una galactosemia fuera del período neonatal, se determinarán los niveles bioquímicos de los metabolitos y la actividad enzimática y posteriormente se realizará estudio genético.\n\nAnte un neonato en el que se sospeche una galactosemia, con un primer screening positivo o con antecedentes familiares se debe comenzar tratamiento dietético adecuado en espera de los resultados para evitar secuelas.\n---\n226      BLOQUE: HIDRATOS DE CARBONO\n\nEn caso de que existan anteced\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}